Yuhan Corporation, Boehringer Ingelheim Korea 'Join Hands' on Healthcare Innovation

The two companies have built a strong partnership since 2010
They will collaborate across multiple areas to advance Korea's healthcare ecosystem

Yuhan Corporation announced on October 30 that it had signed a strategic memorandum of understanding (MOU) with Boehringer Ingelheim Korea to promote healthcare innovation and contribute to the sustainable development of Korea's healthcare ecosystem.

The two companies have built a long-term partnership since launching the co-promotion of Twynsta, a hypertension treatment, in Korea in 2010. They have also worked together to supply and market major treatments in Korea, including Trajenta and Jardiance. More recently, they expanded their collaboration beyond chronic conditions such as hypertension and diabetes to include cerebrovascular diseases.

Ivan Blanaric, Head of Regional Business for Human Pharmaceuticals at Boehringer Ingelheim (left), and Cho Wookje, CEO of Yuhan Corporation, pose for a commemorative photo after signing a memorandum of understanding (MOU). Yuhan Corporation

Under the agreement, the companies plan to expand their collaboration around three strategic pillars: ▲ advancing healthcare innovation and ecosystem development beyond their existing business cooperation; ▲ expanding patient benefits by combining complementary global and local expertise; and ▲ establishing a foundation for joint efforts to create a sustainable healthcare ecosystem and enhance patient value.

Specifically, they will explore joint initiatives to drive healthcare innovation in areas including digital healthcare and patient support programs, efforts to raise disease awareness and promote early diagnosis, medical education and scientific exchange, and improved patient access. The companies will also explore ways to collaborate by leveraging their expertise in key therapeutic areas, including cardiovascular, renal, and metabolic diseases (CRM), through the introduction of innovative medicines, clinical, medical, and scientific cooperation, and the generation of real-world evidence (RWE).

They also plan to identify long-term collaboration models to support the sustainability of Korea's healthcare system and enhance patient value through engagement with a range of stakeholders. To this end, they will consider establishing and operating a joint working group.

Cho Wookje, CEO of Yuhan Corporation, said, "Building on Yuhan Corporation's accumulated research and development and business capabilities, as well as our deep understanding of Korea's healthcare environment, we will strive to help expand treatment benefits for patients in Korea and advance the healthcare ecosystem."

Anna Maria Boy, CEO of Boehringer Ingelheim Korea, said, "Through this agreement, we will broaden our collaboration beyond the supply of medicines to encompass healthcare innovation and the healthcare ecosystem as a whole, and deliver sustainable value to patients in Korea and society."

This content was produced with the assistance of AI translation services.